SNPMiner Trials (Home Page)
Report for Clinical Trial NCT01259050
Developed by Shray Alag, 2020.
SNP Clinical Trial Gene
The purpose of this study is to determine the safety of Zinc given at 90mg/d in conjunction
with 2mg/d of copper in ALS patients.
Name: Zinc and Copper
Description: Optizinc 90 mg/d Copper 1 mg
Group Labels: 1 Zinc and Copper
Primary Outcomes Measure: To evaluate the safety of high doses of zinc in patients with ALS Time: 1 year
Secondary Outcomes Measure: Measure levels of BMAA in blood and urine to determine if there is a decline in these levels over the course of treatment Time: 1 year
Single Group Assignment
There is one SNP
Previous studies have shown that in ALS
mutant G93A SOD transgenic mice, actual zinc supplementation delayed death. --- G93A ---